Nausea Clinical Trial
Official title:
Intra-abdominal at Cesarean Section: A Randomized Controlled Trial
The purpose of this study is to determine if intra-abdominal irrigation at the time of
cesarean delivery increased maternal GI discomfort without affecting infection rates.
We hypothesized that avoiding intra-operative irrigation at the time of cesarean delivery
will decrease intra-operative nausea and vomiting without increasing maternal infectious
morbidity, post-operative pain, return of bowel function, or time to discharge.
This study will be a prospective randomized controlled trial.
Based on available literature and clinical experience, we expect a twenty percent decrease
in gastrointestinal disturbances by avoiding intraoperative irrigation at the time of
cesarean section. With the type 1 error rate set at 0.05 and a power of 0.90; this will
require 184 patients in each arm (irrigation versus no irrigation) to obtain an adequate
sample size. Paper copies of written consent and any identifying information will be kept in
a secured, locked file. All data collected will be stored in a password protected computer
file that will be accessible only to the investigators.
Patients will be identified at the time of admission to the Labor and Delivery unit. A
physician will discuss the study with the patient. After time for consideration and having
had all questions answered the patient will then be consented for the trial. Consent will be
obtained at the time of admission to the Labor and Delivery unit. If the patient has a
successful vaginal delivery the patient will not enter the study. If the patient requires a
cesarean section the patient will be randomized either in to an irrigation or a
nonirrigation group. Assignment will be performed by pulling sequentially numbered opaque
envelopes containing computer-randomized individual allocations. This randomization will be
carried out by research staff before the initiation of the study, and the patients will be
blinded to treatment once assigned. Information regarding basic demographic data,
comorbidities that may affect infection rates (diabetes, hypertension, ect), interventions
during labor, and post partum course will be obtained from the patients' charts.
The two arms will differ only in intraoperative management of the patient after delivery of
the baby. Patients in the irrigation arm will receive a cesarean section with irrigation of
the abdominal cavity with 500-1000mL of warm normal saline after closure of the uterine
incision but prior to the closure of the abdominal wall. In addition all blood clots and
other debris will be evacuated from the paracolic gutters, anterior and posterior culdesacs,
and under the bladder flap. The nonirrigation group will receive Joel-Cohen cesarean section
without the irrigation with normal saline. This group will also have any large debris
including blood clots evacuated. Both groups will undergo standard closure of the abdominal
wall, including reapproximation of the rectus muscles and suturing of the rectus fascia with
running nonlocking absorbable suture. Prefascial irrigation of the subcutaneous tissues
superior to the closed fascia will be done in both groups. Staples or absorbable suture will
be used for skin closure. In addition all patients will receive a standardized dose of 1
gram of a first generation cephalosporin or 900mg clindamycin intravenously as antibiotic
prophylaxis at the time of umbilical cord clamping.
As per standard of care, the post partum care will include vital signs every 4 hours
including patient report of pain level and nausea, discontinuation of the foley catheter and
advancement of the diet on postoperative day one, daily examination of the incision,
notation of return of gastrointestinal function, early ambulation, and a complete blood
count on the first postoperative day.
The primary outcome of measure will be maternal GI disturbance. This will be defined as
nausea or emesis during the cesarean section as well as any nausea requiring medical
intervention during her hospitalization. The time to return of bowel function will also be
recorded. The secondary outcome of measure is the incidence of maternal infectious
morbidity, defined as endometritis. This will be diagnosed with two or more of the following
are present: abnormally tender uterus on exam, temperature greater than 100.4°F at any time
postoperatively, unexplained maternal tachycardia greater than 100 beats per minute.
Patients will also be monitored for wound infections daily by visual inspection of the
incision. Diagnosis will be made if any erythema, tenderness, discharge or separation occurs
with maternal fever. Post operative care providers will be blinded to group assignment to
avoid any potential bias.
The investigators will collect the data, perform data entry, and review charts to ensure
accuracy of information provided by the treating physician. Periodic reviews of the data
entry will be performed to ensure completeness and accuracy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
| Completed |
NCT02939287 -
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
|
Phase 3 | |
| Not yet recruiting |
NCT06464926 -
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
|
N/A | |
| Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
| Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
| Completed |
NCT02462811 -
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
|
Phase 3 | |
| Completed |
NCT01007500 -
Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
|
Phase 4 | |
| Recruiting |
NCT00528554 -
Laser Acupuncture Against Nausea in Children
|
N/A | |
| Completed |
NCT00537875 -
Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
|
N/A | |
| Completed |
NCT00394966 -
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT00946387 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT00947128 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
|
Phase 1 | |
| Recruiting |
NCT05433636 -
Mindful Waiting Room
|
N/A | |
| Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
| Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
| Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
| Recruiting |
NCT04181346 -
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
| Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
| Completed |
NCT02618343 -
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
|
N/A | |
| Terminated |
NCT01405924 -
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
|
Phase 2 |